As global healthcare systems prepare for 2025, the demand for high-quality injectable medicines continues to rise. Products like Simaglutide, Isoflurane, Enoxaparin, and Human Albumin are now critical for diabetes care, anesthesia, thrombosis management, and intensive therapies. At the same time, buyers are under pressure to manage global pharmaceutical pricing, ensure regulatory compliance, and secure uninterrupted